These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 9476145)
1. Intracellular pharmacokinetics of anthracyclines in human leukemia cells: correlation of DNA-binding with apoptotic cell death. Gieseler F; Nüssler V; Brieden T; Kunze J; Valsamas S Int J Clin Pharmacol Ther; 1998 Jan; 36(1):25-8. PubMed ID: 9476145 [TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells. Bogush T; Robert J Anticancer Res; 1996; 16(1):365-8. PubMed ID: 8615637 [TBL] [Abstract][Full Text] [Related]
3. Dual mechanism of daunorubicin-induced cell death in both sensitive and MDR-resistant HL-60 cells. Côme MG; Skladanowski A; Larsen AK; Laurent G Br J Cancer; 1999 Mar; 79(7-8):1090-7. PubMed ID: 10098741 [TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetics and action mechanism of anthracyclines]. Fukushima T; Ueda T; Nakamura T Gan To Kagaku Ryoho; 1992 Apr; 19(4):445-50. PubMed ID: 1558393 [TBL] [Abstract][Full Text] [Related]
5. Single-strand DNA breaks induced by chromophore-modified anthracyclines in P388 leukemia cells. Capranico G; Soranzo C; Zunino F Cancer Res; 1986 Nov; 46(11):5499-503. PubMed ID: 3463414 [TBL] [Abstract][Full Text] [Related]
6. E1A overcomes the apoptosis block in BCR-ABL+ leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents. Stiewe T; Parssanedjad K; Esche H; Opalka B; Pützer BM Cancer Res; 2000 Jul; 60(14):3957-64. PubMed ID: 10919674 [TBL] [Abstract][Full Text] [Related]
7. Relationship between topoisomerase II-DNA cleavable complexes, apoptosis and cytotoxic activity of anthracyclines in human cervix carcinoma cells. Gruber BM; Anuszewska EL; Bubko I; Gozdzik A; Priebe W; Fokt I Anticancer Res; 2005; 25(3B):2193-8. PubMed ID: 16158963 [TBL] [Abstract][Full Text] [Related]
8. Induction of apoptosis by idarubicin: how important is the plasma peak? Gieseler F; Clark M; Stiebeling K; Puschmann M; Valsamas S Int J Clin Pharmacol Ther; 2000 Apr; 38(4):217-21. PubMed ID: 10783832 [TBL] [Abstract][Full Text] [Related]
9. 123I-ITdU-mediated nanoirradiation of DNA efficiently induces cell kill in HL60 leukemia cells and in doxorubicin-, beta-, or gamma-radiation-resistant cell lines. Reske SN; Deisenhofer S; Glatting G; Zlatopolskiy BD; Morgenroth A; Vogg AT; Buck AK; Friesen C J Nucl Med; 2007 Jun; 48(6):1000-7. PubMed ID: 17504875 [TBL] [Abstract][Full Text] [Related]
11. WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity. Faderl S; Estrov Z; Kantarjian HM; Harris D; Van Q; Fokt I; Przewloka T; Godlewski C; Woynarowski JM; Priebe W Anticancer Res; 2001; 21(6A):3777-84. PubMed ID: 11911247 [TBL] [Abstract][Full Text] [Related]
12. Efflux kinetics and intracellular distribution of daunorubicin are not affected by major vault protein/lung resistance-related protein (vault) expression. van Zon A; Mossink MH; Schoester M; Scheper RJ; Sonneveld P; Wiemer EA Cancer Res; 2004 Jul; 64(14):4887-92. PubMed ID: 15256459 [TBL] [Abstract][Full Text] [Related]
13. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line. Cinti C; Claudio PP; Luca AD; Cuccurese M; Howard CM; D'Esposito M; Paggi MG; Sala DL; Azzoni L; Halazonetis TD; Giordano A; Maraldi NM Oncogene; 2000 Oct; 19(44):5098-105. PubMed ID: 11042698 [TBL] [Abstract][Full Text] [Related]
14. Idarubicin: a brief overview on pharmacology and clinical use. Borchmann P; Hübel K; Schnell R; Engert A Int J Clin Pharmacol Ther; 1997 Feb; 35(2):80-3. PubMed ID: 9147715 [TBL] [Abstract][Full Text] [Related]
15. Cell surface-directed interaction of anthracyclines leads to cytotoxicity and nuclear factor kappaB activation but not apoptosis signaling. Maestre N; Tritton TR; Laurent G; Jaffrézou JP Cancer Res; 2001 Mar; 61(6):2558-61. PubMed ID: 11289131 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia. Szmigielska-Kaplon A; Smolewski P; Najder M; Robak T Ann Hematol; 2002 Sep; 81(9):508-13. PubMed ID: 12373351 [TBL] [Abstract][Full Text] [Related]
17. Evidence that the apoptotic actions of etoposide are independent of c-Jun/activating protein-1-mediated transregulation. Jarvis WD; Johnson CR; Fornari FA; Park JS; Dent P; Grant S J Pharmacol Exp Ther; 1999 Sep; 290(3):1384-92. PubMed ID: 10454518 [TBL] [Abstract][Full Text] [Related]
18. Repair of idarubicin-induced DNA damage: a cause of resistance? Dartsch DC; Gieseler F DNA Repair (Amst); 2007 Nov; 6(11):1618-28. PubMed ID: 17616443 [TBL] [Abstract][Full Text] [Related]
19. Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Costello RT; Mallet F; Gaugler B; Sainty D; Arnoulet C; Gastaut JA; Olive D Cancer Res; 2000 Aug; 60(16):4403-11. PubMed ID: 10969785 [TBL] [Abstract][Full Text] [Related]
20. Resistance of mitochondrial DNA to degradation characterizes the apoptotic but not the necrotic mode of human leukemia cell death. Tepper CG; Studzinski GP J Cell Biochem; 1993 Jul; 52(3):352-61. PubMed ID: 8366146 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]